• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
173377 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  ( E8 [; J- I  W/ t- _  P" y" N

. e; g3 q! d% `5 h
& q0 z' Y2 n. S% q( V& lSub-category:# E8 ^" `4 T! F* o
Molecular Targets
- w& J& ?$ F3 ^( a
3 B/ a) E9 J% O2 Y- X9 |' j
9 J  O, }% T* CCategory:- X" `4 E0 L- O: O7 B, w. G
Tumor Biology
# Q4 m& U% e; R" i( Y9 k  P9 I) F( Q9 E& }7 w; E3 D: y2 \: g
& y% m% N# m% G4 U
Meeting:: ^* ^8 V/ k% M' X3 p, l4 K: m
2011 ASCO Annual Meeting ) s; u' @: }. |9 w3 H9 W/ `

& x! n  ]  v1 O% W- q. w# v& ~, }3 B$ K
Session Type and Session Title:0 A( Y& U- W# k' K, o  s5 n* T
Poster Discussion Session, Tumor Biology
. n9 G2 {$ B! D7 o3 y) V( H" I& {& [" Q4 E5 i5 L( @6 ~
4 d9 Y) s: V) N# ]" ?% N
Abstract No:
$ O' e0 n* n! G! H% B10517 : V* R3 ]# c4 e( l
: R  _) K3 _% b, w
0 O2 K3 x, C! B" L: L0 s
Citation:& V  j, x% O* y" m
J Clin Oncol 29: 2011 (suppl; abstr 10517) . |7 B; ?3 q+ A) }* v
6 T( e, M& t$ Q4 j
1 Q3 Q6 y) v6 y: L2 b  e
Author(s):
  p6 }) i; U( S" A6 k- H$ b& w, fJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
1 F$ k  Z9 F/ D
9 j$ a* k$ C# w5 V% n" c0 s
- j$ j4 T# m2 r2 j" N$ u; M
+ O" z) J" N$ M# QAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings./ z7 H* L( X: m0 R% l: b  ^" D+ O

- z1 a9 y! {6 }  t! kAbstract Disclosures
' }# J( @& _6 @  W/ ?: E* l+ l6 q$ A: O: \
Abstract:7 K7 p  ]2 i8 @

3 g0 ?" V6 v; Z* g8 A7 N
' _9 V5 P  o) I" wBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.8 u# M" C9 h# m
+ ?6 _9 h- U- T; u4 g* |

1 A, F$ O3 L! n! E4 K. C4 H
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
0 Q$ |  U7 [2 v, ~- k没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
/ T; `& q0 s5 `0 O/ F
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
$ q* j7 ^* l  R2 u* M易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。6 c4 g1 S; h/ y1 g1 k
ALK一个指标医院要900多 ...

2 {6 t0 y/ A1 g5 z平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
0 e9 ?' V/ a7 T, ~- _- [( [' q3 G/ a( v3 a1 q# O, v
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表